Browsing by Subject "head and neck"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Proton Therapy for Head and Neck Adenoid Cystic Carcinoma: Initial Clinical Outcomes
    (Wiley, 2015-01) Linton, Okechukwu R.; Moore, Michael G.; Brigance, Joseph S.; Summerlin, Don-John; McDonald, Mark W.; Department of Otolaryngology Head & Neck Surgery, IU School of Medicine
    Background The purpose of this study was to report outcomes of proton therapy in head and neck adenoid cystic carcinoma. Methods We conducted a retrospective analysis of 26 patients treated between 2004 and 2012. Twenty patients (77%) had base of skull involvement; 19 (73%) were treated for initial disease and 7 (27%) for recurrent disease. Twenty patients were treated postoperatively, 6 after biopsy alone and 24 had positive margins or gross residual disease. Median dose delivered was 72 Gy (relative biological effectiveness [RBE]). Results Median follow-up was 25 months (range, 7–50 months). The 2-year overall survival was 93% for initial disease course and 57% for recurrent disease (p = .19). The 2-year local control was 95% for initial disease and 86% for recurrent disease (p = .48). The 2-year distant metastatic rate was 25%. Late toxicity of grade 0 or 1 was seen in 17 patients, grade 2 in 5, grade 3 in 2, grade 4 in 1, and grade 5 in 1. Conclusion Initial outcomes of proton therapy are encouraging. Longer follow-up is required.
  • Thumbnail Image
    Item
    Squamous Cell Carcinoma: PET/CT and PET/MRI of the Pretreatment and Post-Treatment Neck
    (Elsevier, 2019) Traylor, Katie S.; Koontz, Nicholas; Mosier, Kristine; Radiology and Imaging Sciences, School of Medicine
    The incidence of head and neck cancer continues to rise annually, most commonly squamous cell carcinoma (SCCa). Advances in imaging techniques have improved diagnostic accuracy with important ramifications for initial staging and post-treatment surveillance. FDG-PET/CT and, more recently, FDG-PET/MRI have revolutionized the staging and surveillance of head and neck SCCa. We detail the diagnostic role of FDG-PET/CT and FDG-PET/MRI of SCCa at the different head and neck subsites, highlighting their role in identifying the primary tumor extent, regional nodal metastases, and distant metastatic disease in the pretreatment and post-treatment setting, as well as implications for staging, treatment, and prognosis.